Genetic studies provide valuable information to assess if the effect of genetic variants varies by the non-genetic ("environmental") variables, what is traditionally defined to be gene-environment interaction. A common complication is that multiple disease states present with the same set of symptoms, and hence share the clinical diagnosis.
INTRODUCTION
Numerous genome-wide association studies (GWAS) have been conducted to estimate how the effect of genetic variants varies by non-genetic (environmental) variables, what is traditionally referred to as gene-environment interactions (GxE) . A major and commonly overseen complication is that multiple distinct pathophysiologic mechanisms might present with the same set of symptoms and hence the same clinical diagnosis.
Frequencies of the disease states within the clinically diagnosed set often vary by the environmental variables, such as age, race/ethnicity. The pathophysiologic mechanisms underlying the disease states might have distinct genetic bases. Hence the analyses with the clinical diagnosis as an outcome variable might miss important associations or result in spurious findings (Carroll et al, 2016) .
Our study is motivated by the setting of Alzheimer's disease (AD) where approximately 30% of patients clinically diagnosed with AD do not have evidence of amyloid deposition as measured by positron emission tomography (PET) .
Hence two disease states -symptoms of AD with amyloid evidence and symptoms of AD with no amyloid evidence -are within the clinical diagnosis of AD. We define the disease state of AD with amyloid evidence to be the disease state of interest (Potter and Wisniewski, 2012) . Frequencies of the disease states within the clinical diagnosis are estimated to vary by age and Apolipoprotein (ApoE) of AD increases and the age at onset decreases with the number of ApoE ߝ 4 alleles (Corder et al, 1993; Farrer et al, 1997) , thus suggesting a GxE. Because the disease states of AD with and without the amyloid evidence might have distinct genetic bases and the mechanism of ApoE ߝ 4 action might be relevant to the amyloid deposition, we are interested to assess the GxE in the relationship to the disease state of AD underlined by the amyloid evidence.
Our previous studies showed both empirically and theoretically that ignoring heterogeneity of AD diagnosis can lead to severely biased estimates of GxE (Lobach et et al, 2018; Lobach et al, 2019) .
We are interested to estimate the GxE from the set of clinically diagnosed cases only, assuming that G and E are distributed independently in the population. This interest is supported by the prior statistical literature showing that when the genotype and environment are distributed independently in the population and when the disease is rare, the GxE can be estimated from a case-only study more efficiently than from a case-control study (Piegorsch et al, 1994) . This result, however, is not applicable to our setting both because the disease state and the clinical diagnoses are common, and because the clinical diagnosis is not a surrogate of the disease state. We, therefore, are interested to derive what types of GxE can be estimated from the set of clinically diagnosed cases and compare variability of case-control vs. case-only estimates.
Our paper proceeds as follows. We first describe the setting and derivations in the Case-control vs. case-only Estimates section. Next, we evaluate the estimates in empirical studies and describe the setting and results in the Simulation Studies section.
The application of the methods is then shown on a large-scale study of Alzheimer's disease. We conclude the paper with brief discussion.
Materials and Methods

Case-control vs. case-only estimates
We consider a study consisting of 
For clarity of the presentation we will assume that the set of controls is homogeneous, i.e.
For clarity of the presentation we suppose that all variables are binary.
We define
be the distribution of genotype in the population according to Hardy-Weinberg Equilibrium.
We define frequencies of the genotype and environment within the clinical diagnosis and the disease states to be
We are interested to assess GxE. The traditional analyses are based on the logistic regression model, where GxE is a multiplicative interaction capturing the deviation from the sum of main effects of G and E. We hence start by considering a logistic regression models with the disease state of interest as an outcome variable, where the interaction term is of the primary interest. In the context of this study we are not interested in estimating the main effects and hence the risk model itself, we are just aiming to assess if the data provides sufficient evidence for an interactive effect. Hence consider a model is then
and can be estimated in a case-control study as
The case-only estimate is
which is not applicable to our study for two reasons. First, because the disease states and the clinical diagnosis are not rare. Second, because some of the clinically diagnosed cases are misdiagnosed controls.
The case-control GxE estimate (5) cannot be seamlessly reduced to a case-only estimate following the arguments of Piegorsh et al (1994) mainly because the disease state and the clinical diagnosis are not rare.
Hence, we are interested to derive other estimates that characterize how the effect of genotype varies by the environment and that can be estimated in a set of clinically diagnosed cases. We aim to derive estimates of GxE that are necessary and might not be sufficient for evaluating whether or not GxE is present.
It can be easily seen that the environment-specific odds of genotype among cases with the disease state of interest is
Recall that
and then the environment-specific risk ratio attributable to genotype is
From the statistical literature, including the study by Piegorsh et al (1994), we know that a case-only estimate for GxE can be obtained from regressing the environment on the genotype within the set of cases. i.e. a case-only estimate of GxE is the coefficient
The coefficient ߙ ா defines GxE on the relative risk scale. Then this model in combination with (6) arrives at
The analog of model (8) with the clinical diagnosis as an outcome variable is
Hence the case-only GxE coefficient ߙ ா can be estimated from the set of clinically diagnosed cases as
We assume that frequency of genotype, ߠ , and frequencies of the disease states within the clinical diagnosis,
Then variance of the risk ratios (7) and (11) is
Similarly, variance of the odds (6) is
Remarks:
1. If the clinical diagnosis is rare in the population, i.e. ߨ ௗ ൎ 0 , then we can see from (5) 7) , and the coefficient ߙ ா (9).
5. All the risk ratios and odds ratios that we discussed can be easily redefined to be genotype-specific, for example the genotype-specific odds of the environment (3) and (4) with the clinical diagnosis in place of the disease state. We also assess performance of the odds (6), the risk ratio (7), and the estimate (11); and their variances (12) 
We let . Shown in Table 1A are biases, SDs in the estimates, as well as false discovery rates (FDR). We note that the FDR in the estimates that use the clinical diagnosis as an outcome variable ranges between 0.06 and 0.40 across the settings we considered. Hence these inferences can be substantially inflated. The estimates with the disease state as an outcome variable, i.e. (5) and (11), are nearly unbiased. The case-only estimates tend to have variability that is less or equal to the variability of the case-control estimates, with relative efficiency varying from 1 to 2.4. Shown in Table   1B are the odds (6) and risk ratio (7). The estimates are nearly unbiased with empirical variability that is approximately the same as the theoretical variance (12), as shown in Table 1C .
Setting 2:
. We then consider a setting where
. Estimates
shown Table 2A can be substantially biased when the clinical diagnosis is used in place of the outcome variable, while the bias in nearly removed when the disease state is the outcome. The case-only estimates tend to have variability that is smaller than the variability of the case-control estimates with relative efficiencies varying between 1 and 1.7. Risk ratio estimates in Table 2B are nearly unbiased with empirical variability that is close to the theoretical as shown in Table 2C .
Alzheimer's disease study
We applied the proposed analyses to a dataset collected as part of the Alzheimer's Disease Genetics Consortium (Naj et al, 2011 noncarriers aged 75+ clinically diagnosed with AD have evidence of amyloid deposition. We assume that 1 in 10 is diagnosed with AD (https://www.alzheimers.net/resources/alzheimers-statistics/). We will perform sensitivity analyses by assuming these rates and also varying the rates to see how the estimates of ApoE ߝ 4
-by-age interaction might change.
In 
Discussion
We've derived case-control and case-only estimates of GxE with respect to the AD disease state underlined by amyloid deposition in the setting when the disease state is not measured, instead frequencies of the disease state within the clinical diagnosis are estimated in a reliability study. We also evaluated bias and false discovery rates for when the misclassification of the clinical diagnosis is ignored. The setting we consider is unique in that the disease states and the clinical diagnosis are common and that rates of the disease state of interest within the clinical diagnosis vary by G and by E.
The development of our study is motivated by the need to assess presence of GxE, as opposed to estimating all parameters in a risk model, e.g. (1). We are interested to estimate the degree to which the effect of genotype varies by the "environment", such as age, sex, education, race/ethnicity, etc. The setting that we've developed offers an advantage of not having to rely on the estimates of main effects.
In simulation experiments we showed that ignoring misclassification of the clinical diagnosis can result in substantial inflation of false positive rates in GxE. Similarly to the original study by Piegorsch et al (1994) , we note that the variability of case-only estimates is generally smaller than the variability of the case-control estimates.
The derivations that we've developed rely on estimates of the population frequencies of the disease states of interest within the clinical diagnosis that vary by G and E. These estimates are often available. We advocate for sensitivity analyses by assuming the estimates obtained in reliability studies and varying the values slightly to see if the GxE estimates change.
While our study is motivated by the setting of Alzheimer's disease, the general development is applicable to other complex diseases and other settings, e.g. analyses of association in the context of the electronic health records, or other types of genetic data, e.g. gene expression. For example, studies of diabetes (Manchia et al, 2013 ) and
analyses of electronic health records (Hubbard et al, 2017) .
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